Comparison of total body irradiation versus non- total body irradiation containing regimens for de novo acute myeloid leukemia in children.


  • 影响因子:4.07
  • DOI:10.3324/haematol.2020.249458
  • 作者列表:"Dandoy CE","Davies SM","Ahn KW","He Y","Kolb AE","Levine J","Bo-Subait S","Abdel-Azim H","Bhatt N","Chewing J","Gadalla S","Gloude N","Hayashi R","Lalefar NR","Law J","MacMillan M","O'Brien T","Prestidge T","Sharma A","Shaw P","Winestone L","Eapen M
  • 发表时间:2020-06-18

With limited data comparing hematopoietic cell transplant outcomes between myeloablative total body irradiation (TBI) containing and non-TBI regimens in children with de novo acute myeloid leukemia, the aim of this study was to compare transplant-outcomes between these regimens. Cox regression models were used to compare transplant-outcomes after TBI and non-TBI regimens in 624 children transplanted between 2008 and 2016. Thirty two percent (n=199) received TBI regimens whereas 68% (n=425) received non-TBI regimens. Five-year non-relapse mortality was higher with TBI regimens (22% vs. 11%, p<0.0001) but relapse was lower (23% vs. 37%, p<0.0001) compared to non-TBI regimens. Consequently, overall (62% vs. 60%, p=1.00) and leukemia-free survival (55% vs. 52%, p=0.42) did not differ between treatment groups. Grade II-IV acute GVHD was higher with TBI regimens (56% vs. 27%, p<0.0001) but not chronic GVHD. The 3-year incidence of gonadal or growth hormone deficiency was higher with TBI regimens (24% vs. 8%, p<0.001) but there were no differences in late pulmonary, cardiac or renal impairment. In the absence of a survival advantage, the choice of TBI or non-TBI regimen merits careful consideration with the data favoring non-TBI regimens to limit the burden of morbidity associated with endocrine dysfunction.


有限的数据比较了含清髓性全身照射 (TBI) 和非 TBI 方案治疗初治急性髓系白血病患儿的造血细胞移植结局,本研究的目的是比较这些方案之间的移植结果。采用 Cox 回归模型比较 2008 年至 624 年间移植的 2016 例儿童 TBI 和非 TBI 方案后的移植结局。2% (n = 199) 接受了 TBI 方案,而 68% (n = 425) 接受了非 TBI 方案。TBI 方案的 5 年非复发死亡率较高 (22% vs. 11%,p<0.0001) 但复发较低 (23% vs. 37%,p<0.0001) 与非 TBI 方案相比。因此,总体 (62% vs. 60%,p = 1.00) 和无白血病生存率 (55% vs. 52%,p = 0.42) 在治疗组之间没有差异。TBI 方案的 II-IV 级急性 GVHD 较高 (56% vs. 27%,p<0.0001),但慢性 GVHD 不明显。TBI 方案的 3 年性腺或生长激素缺乏症发生率较高 (24% vs. 8%,p<0.001),但晚期肺、心脏或肾功能损害无差异。在缺乏生存优势的情况下,TBI 或非 TBI 方案的选择值得仔细考虑,数据有利于非 TBI 方案,以限制与内分泌功能障碍相关的发病率负担。



作者列表:["Yakoub-Agha I","Chabannon C","Bader P","Basak GW","Bonig H","Ciceri F","Corbacioglu S","Duarte RF","Einsele H","Hudecek M","Kersten MJ","Köhl U","Kuball J","Mielke S","Mohty M","Murray J","Nagler A","Robinson S","Saccardi R","Sanchez-Guijo F","Snowden JA","Srour M","Styczynski J","Urbano-Ispizua A","Hayden PJ","Kröger N"]

METHODS::Chimeric antigen receptor (CAR) T cells are a novel class of anti-cancer therapy in which autologous or allogeneic T cells are engineered to express a CAR targeting a membrane antigen. In Europe, tisagenlecleucel (Kymriah™) is approved for the treatment of refractory/relapsed acute lymphoblastic leukemia in children and young adults as well as relapsed/refractory diffuse large B-cell lymphoma, while axicabtagene ciloleucel (Yescarta™) is approved for the treatment of relapsed/refractory high-grade B-cell lymphoma and primary mediastinal B-cell lymphoma. Both agents are genetically engineered autologous T cells targeting CD19. These practical recommendations, prepared under the auspices of the European Society of Blood and Marrow Transplantation, relate to patient care and supply chain management under the following headings: patient eligibility, screening laboratory tests and imaging and work-up prior to leukapheresis, how to perform leukapheresis, bridging therapy, lymphodepleting conditioning, product receipt and thawing, infusion of CAR T cells, short-term complications including cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, antibiotic prophylaxis, medium-term complications including cytopenias and B-cell aplasia, nursing and psychological support for patients, long-term follow-up, post-authorization safety surveillance, and regulatory issues. These recommendations are not prescriptive and are intended as guidance in the use of this novel therapeutic class.

关键词: 暂无
翻译标题与摘要 下载文献
来源期刊:Oncology reports
作者列表:["Li C","Xu Y","Xin P","Zheng Y","Zhu X"]

METHODS:The aim of the present study was to explore the possible mechanisms of phosphatase and tensin homolog (PTEN) in the pathogenesis of Burkitt's lymphoma, and provide novel information that can be used in the targeted treatment of this disease. PTEN lentiviral overexpression vector and short‑hairpin PTEN silencing vectors were constructed. The effect of PTEN on the growth and proliferation of CA46 and RAJI cells was analyzed using a Cell Counting Kit‑8 assay. Apoptosis was detected by Hoechst 33342 and propidium iodide double staining. Flow cytometry was used to analyze the cell cycle. A Transwell chamber was used to detect cell migration and invasion abilities. Western blot analysis was used to detect related protein changes. The mechanism of the effect of PTEN on the biological characteristics of Burkitt's lymphoma cells was subsequently analyzed. The results revealed that PTEN inhibited the proliferation of CA46 and RAJI cells by downregulating the expression of p‑AKT, It was indicated that the upregulation of proapoptotic proteins (including Bad and Bax) induced apoptosis, regulated cyclin (including P53, P21, CDK4, CDK6, cyclin D3 and cyclin H) to inhibit cell cycle progression, and mediated epithelial‑mesenchymal transition‑like cell markers (including E‑cadherin, N‑cadherin, β‑catenin, TCF‑8, vimentin, Slug and Snail) to inhibit cell migration and invasion. In conclusion, the tumor‑suppressor gene PTEN inhibited the phosphoinositide 3‑kinase/protein kinase B (PI3K/AKT) signaling pathway and inhibited the proliferation and migration of Burkitt's lymphoma cells, induced apoptosis and cell cycle arrest, thus playing a crucial role in the pathogenesis of Burkitt's lymphoma.

关键词: 暂无
翻译标题与摘要 下载文献
作者列表:["Yan G","Lei H","He M","Gong R","Wang Y","He X","Li G","Pang P","Li X","Yu S","Du W","Yuan Y"]

METHODS:Melatonin (Mel) has been shown to involve in many essential cell functions via modulating many signaling pathways. We for the first time investigated that Mel exerted anti-tumor activities in Hodgkin lymphoma (HL) via inhibiting cell proliferation and promoting cell apoptosis. Further study revealed that Mel treatment increased expression of LC3-II and decreased p62 proteins with the enhanced production of autolysosome, indicating it induced activation of autophagy. Nevertheless, Mel treatment together with autophagy inhibitors 3-MA or CQ exacerbated the damage effect of Mel in HL cells, which means autophagy plays a protective role in this process. Furthermore, we found Mel treatment increased the expression of G protein-coupled receptors MT2 and retinoic acid-related orphan receptors (RORs), eg. RORA, RORB and RORC. While RORC has the highest increase in Mel treated HL cells. In addition, RORC overexpression induced autophagy activation. Therefore, Mel showed tumor-suppressive role due to an increased level of RORC induced autophagy in HL.